Incidence, Risk Factors, and Outcomes of De Novo Malignancy following Kidney Transplantation

被引:1
作者
Chukwu, Chukwuma A. [1 ]
Wu, Henry H. L. [2 ]
Pullerits, Kairi [3 ]
Garland, Shona [3 ]
Middleton, Rachel [1 ]
Chinnadurai, Rajkumar [1 ,3 ]
Kalra, Philip A. [1 ,3 ]
机构
[1] Northern Care Alliance NHS Fdn Trust, Dept Renal Med, Salford M6 8HD, England
[2] Univ Sydney, Royal North Shore Hosp, Kolling Inst Med Res, Renal Res Lab, Sydney, NSW 2065, Australia
[3] Univ Manchester, Fac Biol Med & Hlth, Manchester M1 7HR, England
关键词
de novo post-transplant malignancy; kidney transplantation; immunosuppression; risk factors; outcomes; SOLID-ORGAN TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINE; CANCER-RISK; RECIPIENTS; ASSOCIATION; SURVIVAL; DISEASE; PEOPLE; BREAST; COHORT;
D O I
10.3390/jcm13071872
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Post-transplant malignancy is a significant cause of morbidity and mortality following kidney transplantation often emerging after medium- to long-term follow-up. To understand the risk factors for the development of de novo post-transplant malignancy (DPTM), this study aimed to assess the incidence, risk factors, and outcomes of DPTM at a single nephrology centre over two decades. Methods: This retrospective cohort study included 963 kidney transplant recipients who underwent kidney transplantation between January 2000 and December 2020 and followed up over a median follow-up of 7.1 years (IQR 3.9-11.4). Cox regression models were used to identify the significant risk factors of DPTM development, the association of DPTM with graft survival, and mortality with a functioning graft. Results: In total, 8.1% of transplant recipients developed DPTM, and the DPTM incidence rate was 14.7 per 100 patient-years. There was a higher mean age observed in the DPTM group (53 vs. 47 years, p < 0.001). The most affected organ systems were genitourinary (32.1%), gastrointestinal (24.4%), and lymphoproliferative (20.5%). Multivariate Cox analysis identified older age at transplant (aHR 9.51, 95%CI: 2.60-34.87, p < 0.001) and pre-existing glomerulonephritis (aHR 3.27, 95%CI: 1.10-9.77, p = 0.03) as significant risk factors for DPTM. Older age was significantly associated with poorer graft survival (aHR 8.71, 95%CI: 3.77-20.20, p < 0.001). When age was excluded from the multivariate Cox model, DPTM emerged as a significant risk factor for poor survival (aHR 1.76, 95%CI: 1.17-2.63, p = 0.006). Conclusion: These findings underscore the need for tailored screening, prevention, and management strategies to address DPTM in an aging and immunosuppressed kidney transplant population.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study
    Acuna, Sergio A.
    Sutradhar, Rinku
    Kim, S. Joseph
    Baxter, Nancy N.
    [J]. TRANSPLANTATION, 2018, 102 (07) : 1156 - 1164
  • [2] Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis
    Acuna, Sergio A.
    Huang, Johnny W.
    Dossa, Fahima
    Shah, Prakesh S.
    Kim, S. Joseph
    Baxter, Nancy N.
    [J]. TRANSPLANTATION REVIEWS, 2017, 31 (04) : 240 - 248
  • [3] Cancer risk following organ transplantation:: a nationwide cohort study in Sweden
    Adami, J
    Gäbel, H
    Lindelöf, B
    Ekström, K
    Rydh, B
    Glimelius, B
    Ekbom, A
    Adami, HO
    Granath, F
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 (07) : 1221 - 1227
  • [4] De Novo Malignancies after Kidney Transplantation
    Al-Adra, David
    Al-Qaoud, Talal
    Fowler, Kevin
    Wong, Germaine
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (03): : 434 - 443
  • [5] Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant
    Au, Eric H.
    Chapman, Jeremy R.
    Craig, Jonathan C.
    Lim, Wai H.
    Teixeira-Pinto, Armando
    Ullah, Shahid
    McDonald, Stephen
    Wong, Germaine
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 30 (03): : 471 - 480
  • [6] Kinetics of Homeostatic Proliferation and Thymopoiesis after rATG Induction Therapy in Kidney Transplant Patients
    Bouvy, Anne P.
    Kho, Marcia M. L.
    Klepper, Mariska
    Litjens, Nicolle H. R.
    Betjes, Michiel G. H.
    Weimar, Willem
    Baan, Carla C.
    [J]. TRANSPLANTATION, 2013, 96 (10) : 904 - 913
  • [7] Chadban SJ, 2020, TRANSPLANTATION, V104, pS11, DOI 10.1097/TP.0000000000003136
  • [8] Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation
    Cherikh, WS
    Kauffman, HM
    McBride, MA
    Maghirang, J
    Swinnen, LJ
    Hanto, DW
    [J]. TRANSPLANTATION, 2003, 76 (09) : 1289 - 1293
  • [9] ATG-Induced Accelerated Immune Senescence: Clinical Implications in Renal Transplant Recipients
    Crepin, T.
    Carron, C.
    Roubiou, C.
    Gaugler, B.
    Gaiffe, E.
    Simula-Faivre, D.
    Ferrand, C.
    Tiberghien, P.
    Chalopin, J. -M.
    Moulin, B.
    Frimat, L.
    Rieu, P.
    Saas, P.
    Ducloux, D.
    Bamoulid, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 (04) : 1028 - 1038
  • [10] Curry SJ, 2018, JAMA-J AM MED ASSOC, V320, P674, DOI [10.1001/jama.2018.10897, 10.1097/01.ogx.0000549540.69362.81]